Last update 01 Nov 2024

EP300 x CPB x CREBBP

Basic Info

Related Targets
EP300CPBCREBBP

Related

1
Drugs associated with EP300 x CPB x CREBBP
OPN-6602
Target
CPB x CREBBP x EP300
Mechanism
CPB inhibitors [+2]
Active Org.
Opna Bio SAOpna Bio SA
Originator Org.
Opna Bio SAOpna Bio SA
Active Indication
Plasma cell myeloma refractory [+4]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with EP300 x CPB x CREBBP
NCT06433947 / RecruitingPhase 1
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed And/or Refractory Multiple Myeloma
100 Clinical Results associated with EP300 x CPB x CREBBP
Login to view more data
100 Translational Medicine associated with EP300 x CPB x CREBBP
Login to view more data
0 Patents (Medical) associated with EP300 x CPB x CREBBP
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free